Last reviewed · How we verify
NCT03939390: SUBLUTEAL
Follicular Phase Stimulation vs. Luteal Phase Stimulation in Patients Diagnosed With Suboptimal Response
Phase 4 trial testing time of administration of Corifollitropin Alfa in Improving Ovarian Stimulation; Suboptimal Responders in 41 participants. Completed in 2 April 2022.
2 April 2022
Quick facts
| Lead sponsor | Instituto Bernabeu |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 41 |
| Start date | 17 January 2020 |
| Primary completion | 2 April 2022 |
| Estimated completion | 2 April 2022 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- time of administration of Corifollitropin Alfa — full drug profile →
Conditions studied
- Improving Ovarian Stimulation; Suboptimal Responders — all drugs for Improving Ovarian Stimulation; Suboptimal Responders →
Sponsor
Instituto Bernabeu — full company profile →
Who can join
Adults 18 to 41, female only, with Improving Ovarian Stimulation; Suboptimal Responders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to investigate the difference in the number of oocytes obtained by performing ovarian stimulation in follicular phase vs. luteal phase in a population of patients with previous suboptimal response. This is a controlled randomized clinical study. We aim to include 41 patients diagnosed with suboptimal response who will undergo an ovarian stimulation in order to vitrify and accumulate oocytes. The main variable for evaluating the efficacy in this exploratory study will be the number of oocyte cumulus complexes obtained.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Conventional follicular-phase ovarian stimulation vs. luteal-phase stimulation in suboptimal responders: a randomized controlled trial.
Suñol J, Castillo JC, Ortiz JA, Ten J, et al · · 2023 · cited 2× · PMID 38204945 · DOI 10.1016/j.xfre.2023.07.003
Verify or expand the search:
- PubMed search for NCT03939390
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Instituto Bernabeu trials
Trials by the same sponsor.
- NCT07364526 — Non-Invasive Preimplantation Genetic Screening for Aneuploidies and Clinical Outcomes in Egg Donation Patients · recruiting
- NCT07270081 — Follicular Flushing Using Double Lumen Needle Versus Direct Aspiration in Low Prognosis Patients According to the POSEID · NA · completed
- NCT06195163 — TRAP Study: Testosterone for Androgen Receptor Polymorphism · Phase 4 · not yet recruiting
- NCT05954962 — Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation. · Phase 4 · completed
- NCT05815719 — Continuous Double Ovarian Stimulation. · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03939390 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto Bernabeu
- Last refreshed: 6 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03939390.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing